drugset / Trial / NCT06188624
Clinical Trial of TQB2922 for Injection in Patients With Advanced Cancers
Phase 1
Recruiting
150 enrolled
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase I study to evaluate the safety, tolerability, and efficacy of TQB2922 for injection in subjects with advanced cancers
Timeline
- Start
- 2024-02-01
- Primary completion
- 2026-12
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TQB2922 | Unknown | — | — |
Indications
No indication recorded.